Skip to content

Remote Postconditioning in Patients With Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention (PCI)

Pilot Study to Test Feasibility, Safety, Molecular Mediators and Preliminary Efficacy of Remote Myocardial Postconditioning Provided With Extrinsic Cuff Compression of Lower Limb During Primary PCI

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00865722
Acronym
RemPostCon
Enrollment
96
Registered
2009-03-19
Start date
2009-03-31
Completion date
2012-05-31
Last updated
2012-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction, Myocardial Ischemia, Myocardial Reperfusion Injury

Keywords

Remote Postconditioning, Myocardial reperfusion Injury, Myocardial Infarction, Primary PCI

Brief summary

Background: Experimental studies suggest that remote limb ischaemic postconditioning (RemPostCon) can reduce infarct size in pigs. Initial clinical applications support the beneficial role of RemPostCon in preserving endothelial function during upper limb ischemia in healthy volunteers and in patients with stable coronary artery disease. Aim of the study: To evaluate the feasibility, safety and efficacy of RemPostCon in the setting of STEMI and primary PCI (pPCI) and to investigate potential circulating mediators of its effects. Patients and methods: Patients who undergo pPCI for anterior STEMI within 6 hours since the onset of symptoms are randomly assigned to receive either RemPostCon + pPCI or pPCI alone in a single-blind fashion. All patients receive therapy according to the current international guidelines. Three cycles of ischemia-reperfusion are provided to the lower limb inflating a cuff to 200 mmHg. Each cycle consists of 5' of ischaemia, followed by 5' of reperfusion. RemPostCon is started at the time of angioplasty in the infarct related artery. Primary endpoint is the area under the curve (AUC) of creatinine kinase - MB (CK - MB). Cardiac magnetic resonance (CMR) is performed early before discharge and 4 months after the event, if there are no contraindications.

Interventions

PROCEDURERemote Postconditioning

Lower limb compression using a cuff inflated to 200 mmHg for 5 ' followed by 5' of reperfusion fo three times during 30'

Sponsors

Fondazione IRCCS Policlinico San Matteo di Pavia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age \>= 18 yrs AND Age =\< 80 yrs * STEMI definition * Pain to door time \< 6 hrs * Killip class 1 - 2 - 3 * Initial TIMI flow 0 - 1 in the anterior descending artery * Signed informed consent

Exclusion criteria

* Pregnancy * Cardiogenic shock * Initial TIMI flow 2 - 3 in the anterior descending artery * History of prior MI in the past 6 months * History of prior CABG * History of peripheral vascular disease III - IV grade * History of abdominal Aortic Aneurysm \> 5 cm * Severe coronaropathy that could condition further revascularization before the end of the study * Other relevant medical or surgical conditions that can influence prognosis at 4 months

Design outcomes

Primary

MeasureTime frame
Area Under the Curve of CK - MB releasebaseline to 72h since admission

Secondary

MeasureTime frame
TIMI Frame Count30 minutes after first balloon inflation in infarct-related artery
Time to balloonduring pPCI
Ejection Fraction MRIbefore discharge and after 4 months
Myocardial Blush grading30 minutes after first balloon inflation
ST segment resolution6h after balloon
Troponin I peak72h since admission
Area Under the Curve of CK releasebaselinte to 72h since admission
artero-venous differences in pO2, pCO2, pH, HCo3baseline and 30 minutes after first balloon inflation
Major adverse cardiac events4 months since admission
artero-venous quantitative and qualitative differences in endothelial progenitors cells (subgroups)within 24 h since admission
artero-venous Differences of Cytokineswithin 24h since admission
Edema Volume T2 sequences MRIbefore discharge
Delay enhancement volume MRIbefore discharge and after 4 months
Mortality rate4 months since admission

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 22, 2026